Ascelia Pharma AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACE.ST research report →
Companywww.ascelia.com
Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc.
- CEO
- Magnus O. Corfitzen
- IPO
- 2019
- Employees
- 11
- HQ
- Malmö, SE
Price Chart
Valuation
- Market Cap
- $367.92M
- P/E
- -5.19
- P/S
- 0.00
- P/B
- 4.44
- EV/EBITDA
- -4.86
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -72.62%
- ROIC
- -83.93%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-76,253,000 · 4.72%
- EPS
- $-0.67 · 54.73%
- Op Income
- $-74,130,000
- FCF YoY
- -15.06%
Performance & Tape
- 52W High
- $5.23
- 52W Low
- $2.53
- 50D MA
- $3.00
- 200D MA
- $3.22
- Beta
- 0.89
- Avg Volume
- 669.15K
Get TickerSpark's AI analysis on ACE.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ACE.ST Coverage
We haven't published any research on ACE.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ACE.ST Report →